Elizabeth C. Wu

Elizabeth C. Wu

Auto-generated profile, based on publicly available information

Elizabeth C. Wu

Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2025 in Medicine
Verified
Journal Article
Open access
EWElizabeth C. Wu
Elizabeth C. Wu
RHRebecca Hancock-Howard
Rebecca Hancock-Howard
BCBrian C.F. Chan
Brian C.F. Chan
Peter CoytePeter Coyte
Peter Coyte
Background: Acupuncture has been used for pain relief for thousands of years in China, and could be an alternative to drug prophylaxis for migraine prevention. Recently, promising clinical data on acupuncture for migraine prevention has emerged. However, few studies have investigated the economic impact of acupuncture on migraine prevention in Taiwan. Methods: This study aims to assess the lifetime economic impact of acupuncture in migraine prevention from both a Taiwanese healthcare payer and a societal perspective. An economic cost–benefit evaluation was constructed to compare acupuncture with drug prophylaxis and with no active treatment among patients with episodic migraine and chronic migraine over their lifetime in Taiwan. Epidemiological and clinical inputs were collected from the published literature. Healthcare costs and utilization were based on a retrospective longitudinal analysis of the National Health Insurance Research Database. Productivity loss was derived from a labor economic study. Health gains were valued at 3× average national income. All costs were adjusted to 2023 New Taiwan dollars using the consumer price index in Taiwan and reported as the present value with a discount rate of 3%. Results: From both health system and societal perspectives, acupuncture treatment was associated with significantly more lifetime net economic gains than no active treatment ($1,248,464 and $1,321,994, respectively). Similarly, there was a net lifetime economic gain when acupuncture was compared to drug prophylaxis: $909,571 (health system) and $963,510 (societal), respectively. The economic gain of acupuncture was driven by cost savings from reducing productivity loss and increased value from quality-adjusted life-year gain from fewer migraine days. Lifetime economic gain was greatest among young, female, and chronic migraine patients. Conclusion: Acupuncture was associated with greater lifetime net economic gains in migraine prevention compared to no active treatment or drug prophylaxis. Decision-makers in Taiwan should consider increasing reimbursements for acupuncture sessions to encourage its utilization.

19 June 2025 in Medical Acupuncture
Verified
Journal Article
Closed access
EWElizabeth C. Wu
Elizabeth C. Wu
RHRebecca Hancock-Howard
Rebecca Hancock-Howard
BCBrian C.F. Chan
Brian C.F. Chan
PCPeter C. Coyte
Peter C. Coyte
Objective: To assess the lifetime cost-effectiveness of acupuncture in the prevention of episodic migraine from both a Canadian public health care payer and societal perspective. Background: Acupuncture has been used for pain relief for thousands of years in China and could be an alternative to drugs in managing pain. Nevertheless, there is limited evidence to determine if acupuncture is cost-effective in migraine prevention in the Canadian setting. Methods: A cost-utility analysis with a decision-analytic Markov model was constructed to compare acupuncture with drug prophylaxis and no active treatment among adult patients with episodic migraine over their lifetime. The efficacy inputs (migraine days) were based on a Cochrane systematic literature review. Quality-adjusted life years (QALYs) were the modeled health outcome. Direct and indirect medical costs were derived from a Canadian burden of illness study on patients with migraine. All costs were inflated and reported as the present value of lifetime costs in 2021 Canadian dollars (CAD), discounting at 1.5%. Results: From a health system perspective, acupuncture was cost-effective when compared with no active treatment (CAD 35,060/QALY) and drug prophylaxis (CAD 47,128/QALY) at a willingness-to-pay threshold of CAD 50,000/QALY gained. Acupuncture was dominant compared with no active treatment and drug prophylaxis from a societal perspective. Cost savings were driven by reduced productivity loss from fewer migraine days with acupuncture treatment. Conclusion: Acupuncture could be a cost-effective option for patients with episodic migraine. Future studies are encouraged to inform decisions regarding the use of acupuncture in the management of episodic migraine.